Abstract:Background: Previously known as the anti-rejection drug, then famous for its efficacy on many mTOR-regulated diseases, sirolimus is now reported as the drug to reverse the process of many age-related diseases, rejuvenate immunity, and extend life span. However, its long-term safety profile for all-age groups is still a concern.Methods: Data were from two 10-year prospective cohort studies (ChiCTR-OOB-15006535,NCT031938), in which patients were diagnosed with tuberous sclerosis and/or lymphangioleiomyomatosis. Indicators on growth, hematopoietic, liver and renal function, and blood lipid were all primary outcomes. GLM analysis and Chi-square test were used to reveal their changes between the baseline and five follow-up periods (< 6 months, 6 to < 12 months, 1 to < 2 years, 2 to < 4 years, and 4-to-10 years)). Four models with cross-validation were constructed for prediction. Descriptive adverse events and the change of regimens were also recorded (secondary outcomes). Findings: 1738 patients aging from 5 days to 69 years were included. The median follow-up period was 25 (12-43) months, and 380 patients were followed for more than four years. Z scores of height, weight, and BMI increased significantly throughout the follow-up (baseline versus 4-to-10-year follow-up: 0·24 vs 0·69, 0·25 vs 0·56, 0·14 vs 0·29). The dose of sirolimus was the only factor related to all the changes. No negative effects on hematopoietic, liver, and renal function were observed throughout the follow-up. On the contrary, the long-term use of sirolimus showed beneficial effects. The increase of blood lipids was mainly in the first six months. Stomatitis was the most common adverse event (920/1738, 52·9% ), and 48·5% of adult females were with menstrual disorders. The economic burden was the main reason for discontinuing therapy.Interpretation: For the first time, we observed the increase in height and weight brought by sirolimus. Also, the length of follow-up was associated with different safety profiles. Some beneficial effects were observed in a longer follow-up.Clinical Trial Registration Details: The pediatric patients in this study are from the "Efficacy and Safety of Sirolimus in Pediatric Patients with Tuberous Sclerosis (ESOSIPT)" study (Chinese Clinical Trial Registration, http://www.chictr.org.cn, No. ChiCTR-OOB-15006535). The adult patients re from "A National Registry on Chinese Patients with Lymphangioleiomyomatosis" (ClinicalTrials.gov, No. NCT03193892).Funding Information: This work was supported by grants from the National Key Research and Development Program of China (No. 2016YFC1000707,No.2016YFC0901502) and the National Natural Science Foundation of China (No. 81471329).Declaration of Interests: The authors have no conflicts of interest relevant tothis article to disclose.Ethics Approval Statement: The Ethics Committee of Chinese PLA General Hospital approved the pediatric study (No. S2013-028-01). The Ethics Committee of Peking Union Medical College Hospital (PUMCH) approved the adult study(JS-1323).

Sirolimus Improves Seizure Control in Pediatric Patients with Tuberous Sclerosis: A Prospective Cohort Study

Sirolimus Treatment for Tuberous Sclerosis Complex Prior to Epilepsy: Evidence from a Registry-Based Real-World Study

Population Pharmacokinetics and Initial Dose Optimization of Sirolimus Improving Drug Blood Level for Seizure Control in Pediatric Patients With Tuberous Sclerosis Complex

Efficacy and Safety of Mtor Inhibitors (rapamycin and Its Analogues) for Tuberous Sclerosis Complex: a Meta-Analysis

Population Pharmacokinetic Analysis and Dosing Optimization of Sirolimus in Children with Tuberous Sclerosis Complex.

Sirolimus Can Increase the Disappearance Rate of Cardiac Rhabdomyomas Associated with Tuberous Sclerosis: A Prospective Cohort and Self-Controlled Case Series Study

Long-term Administration of Sirolimus Does Not Affect the Physical Development of Children with Tuberous Sclerosis Complex

Everolimus as adjunctive treatment in tuberous sclerosis complex-associated epilepsy in children

Efficacy and Safety of a Mammalian Target of Rapamycin Inhibitor in Pediatric Patients with Tuberous Sclerosis Complex: A Systematic Review and Meta-Analysis.

Safety Profile of Sirolimus in All Age Groups: A Pooled Analysis of Two 10-Year Cohort Studies Comprising 1738 Patients With Tuberous Sclerosis and/or Lymphangioleiomyomatosis

Initial Dosage Recommendation for Sirolimus in Children With Tuberous Sclerosis Complex.

Clinical analysis of sirolimus therapy in children with refractory nephrotic syndrome

A prospective multicenter study of sirolimus for complicated vascular anomalies

Rapamycin in the Treatment of Renal Diseases Associated with Tuberous Sclerosis Complex

Long-term safety and influence on growth in patients receiving sirolimus: a pooled analysis

Optimization and high-density array of stereoelectroencephalography-guided radiofrequency thermocoagulation for the treatment of pediatric tuberous sclerosis complex with epilepsy

Prenatal Diagnosis and Intervention Improve Developmental Outcomes and Epilepsy Prognosis in Children with Tuberous Sclerosis Complex

Sirolimus for vascular anomalies associated with PTEN hamartoma tumor syndrome

Safety of Inactivated COVID-19 Vaccine in Tuberous Sclerosis Complex Patients with Epilepsy Treated with Rapamycin

Therapeutic Drug Monitoring for Sirolimus in Children with Vascular Anomalies: What Can We Learn from a Retrospective Study

Effectiveness of Sirolimus in the Treatment of Complex Lymphatic Malformations: Single Center Report of 56 Cases.